02 October 2024 | Wednesday | News
Image Source : Public Domain
Eisai announced the commencement of full-scale operations at Eisai Pharmaceuticals Single Person Limited Liability Company (Eisai Saudi Arabia), a wholly-owned subsidiary established in Riyadh. This new pharmaceutical sales entity, under the umbrella of Eisai Europe Ltd., marks Eisai's direct entry into the Saudi market after decades of working through local distribution partners.
Eisai’s presence in the Middle East dates back to the 1960s, and in 2009, the company launched its peripheral neuropathy treatment Methycobal® in Saudi Arabia. Since then, it has introduced a range of treatments, including the antiepileptic drug Fycompa® (2018) and the anticancer drug Lenvima® (2020). The establishment of Eisai Saudi Arabia in April 2024 reflects the company's strategic shift to in-house sales and marketing operations, taking over commercial rights from local partners.
October 2024 marks the start of sales activities for Methycobal and Fycompa under the new structure, with plans to expand operations to include Lenvima and the anticancer drug Halaven® in April 2025. In addition, Eisai has submitted an application for the approval of lecanemab (global brand name: Leqembi®), an Alzheimer’s disease treatment, which is currently under review in Saudi Arabia.
Saudi Arabia's pharmaceutical market, valued at USD 11.34 billion in 2023, is the largest in the Middle East and has seen an average growth rate of 7% from 2019 to 2023. With the launch of Eisai Saudi Arabia, Eisai aims to strengthen its presence in this vital market, providing innovative treatments to more patients in the region and improving patient outcomes and care.
Outline of Eisai Saudi Arabia:
Most Read
Bio Jobs
News
Editor Picks